Home > Healthcare > Pharmaceuticals > Vaccines > Shingles Vaccine Market

Shingles Vaccine Market Share

Report ID: GMI12360
Published Date: Nov 2024
Report Format: PDF

Download Free Sample

Shingles Vaccine Market Share

The market is highly competitive, with key players focusing on product innovation, strategic partnerships, and market expansion. GSK leads the market with its Shingrix vaccine, which has demonstrated superior efficacy in preventing shingles and its complications. Shingrix is widely recommended by health authorities, including the CDC, contributing to its strong market presence in North America and Europe. Merck is another major competitor with its Zostavax vaccine, which, although effective, has been largely replaced by Shingrix due to its higher efficacy. The market is characterized by strong competition between companies focused on enhancing vaccine accessibility, improving immunization rates, and expanding insurance coverage to reach a broader demographic.

Shingles Vaccine Market Companies

Prominent players operating in the shingles vaccine industry include:

GSK plc
Merck & Co.
SK bioscience

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global shingles vaccine industry was valued at USD 4.9 billion in 2024 and is expected to grow at a 10.1% CAGR from 2025 to 2034, driven by the rising geriatric population and favorable reimbursement policies.

The Shingrix segment generated USD 4.2 billion in revenue in 2024 due to its recombinant formulation, which provides robust and durable protection against shingles, especially for the aging population.

The North America shingles vaccine market recorded USD 2.7 billion in revenue in 2024 and is anticipated to grow at a 9.6% CAGR from 2025 to 2034, driven by high awareness of shingles prevention and favorable healthcare policies.

Key players in the industry include GSK plc, Merck & Co., and SK bioscience.